Free Trial!
Today’s Best Stocks To Trade! Click Here
Jamba Inc. (NASDAQ: JMBA | news | PowerRating | PR Charts ) through its subsidiary, Jamba Juice Company, owns and franchises JAMBA JUICE stores. The company operates as a retailer of blended-to-order fruit smoothies, squeezed-to-order juices, blended beverages, and snacks in the United States. As of December 31, 2007, it operated approximately 707 stores, of which 501 were company-owned and operated. The company was founded in 1990 and is headquartered in Emeryville, California. With 52.6 million shares outstanding and 9.01 million shares declared short as of January 2008, there is a failure to deliver in shares of JMBA. According to quarterly data provided by the SEC, there were still 10,110 shares of JMBA that were failing-to-deliver as of September 27, 2007.
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX | news | PowerRating | PR Charts ) a biopharmaceutical company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. The company's endocrine/renal products include Sulonex, a Phase III and Phase IV clinical stage product for the treatment of diabetic nephropathy; and Zerenex, a Phase II clinical stage product for the treatment of Hyperphosphatemia in patients with end-stage renal disease. Its oncology products include KRX-0401, a Phase II clinical stage product for the treatment of multiple forms of cancer; KRX-0402, a Phase II clinical stage product for the treatment of brain cancer; KRX-0601, a Phase II clinical stage product for the treatment of multiple forms of cancer; and KRX-0404, a pre-clinical stage product for the treatment of multiple forms of cancer. The company also develops neurology products, including KRX-0501, a pre-clinical stage product for the treatment of neurological disorders. In addition, it offers AccuminTM, a patent protected, diagnostic for the direct measurement of total and intact urinary albumin. It has strategic alliances with Alfa Wassermann S.p.A.; Collaborative Study Group; AEterna Zentaris, Inc.; Panion & BF Biotech, Inc.; Kyowa Hakko Kogyo Co., Ltd.; and AusAm Biotechnologies, Inc. for the manufacture and commercialization of its products. Keryx Biopharmaceuticals was founded in 1998. It was formerly known as Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999. Later, the company changed its name to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals is based in New York, New York. With 43.65 million shares outstanding and 11.16 million shares declared short as of January 2008, there is a failure to deliver in shares of KERX. According to quarterly data provided by the SEC, there were still 16,868 shares of KERX that were failing-to-deliver as of September 28, 2007.
STEN Corp. (NASDAQ: STEN | news | PowerRating | PR Charts ) principally provides financial services in the United States. It provides auto loans to consumers under installment receivable contracts, as well as finances a portion of the dealer-partner vehicle inventory. The company also provides short term consumer loans, such as auto title loans and deferred presentment loans, check cashing, bill payment options, and money wires. In addition, STEN engages in the retail of used cars. Further, it manufactures, on a contract basis, a line of sterilization containers and filters for use by hospitals, clinics, and surgery centers. The company was founded in 1978. It was formerly known as Oxboro Medical International, Inc. and subsequently changed its name to Sterion Incorporated. It further changed its name to STEN Corporation in 2005. The company is headquartered in Minnetonka, Minnesota. With 2.53 million shares outstanding and 5,500 shares declared short as of January 2008, there is a failure to deliver in shares of STEN.
Telik Inc. (NASDAQ: TELK | news | PowerRating | PR Charts ) a biopharmaceutical company, engages in the discovery and development of small molecule therapeutics for the treatment of cancer and inflammatory diseases. Its products include TELCYTA, a small molecule cancer drug product candidate designed to be activated in cancer cells, which is in Phase III clinical trials; TELINTRA, a Phase II clinical trial product, which is a small molecule bone marrow stimulant for the treatment of blood disorders associated with low blood cell levels; and TLK58747, a preclinical testing product, which causes apoptosis and G2/M cell cycle arrest in human cancer cell lines. The company has collaborative agreements for screening services with Sanwa Kagaku Kenkyusho Co., Ltd.; and screening and license agreement with Hoffmann-La Roche, Inc. Telik, Inc. was founded in 1988 as Terrapin Diagnostics, Inc. and changed its name to Telik, Inc. in 1998. The company is based in Palo Alto, California. With 52.6 million shares outstanding and 10.62 million shares declared short as of January 2008, there is a failure to deliver in shares of TELK. According to quarterly data provided by the SEC, there were still 465,204 shares of TELK that were failing-to-deliver as of September 28, 2007.
Jayhawk Energy Inc. (OTCBB: JYHW | news | PowerRating | PR Charts ) a development stage company, engages in the exploration, acquisition, development, production, and sale of natural gas, crude oil, and natural gas liquids primarily from conventional reservoirs in North America. It owns interest in the Uniontown project covering 35,000 gross acres of non-producing coal bed methane natural gas reserves located in Bourbon County, Kansas. The company was founded in 2004 as Bella Trading Company, Inc. and changed its name to JayHawk Energy, Inc. in June 2007. JayHawk Energy, Inc. is based in Broomfield, Colorado. With 36.88 million shares outstanding and 133,900 shares declared short as of January 2008, there is a failure to deliver in shares of JYHW. According to quarterly data provided by the SEC, there were still 22,674 shares of JYHW that were failing-to-deliver as of September 26, 2007.
Timeline Inc. (OTCBB: TMLN | news | PowerRating | PR Charts ) licenses intellectual property protected by patents that are granted by the U.S. Patent and Trademark Office (USPTO) and other countries. Its patents involve technology, which enable substantial automation of the formation and use of data marts that are utilized to provide enhanced reporting and analysis of data captured in various digital format from varying software applications. The company holds a patent portfolio of 7 patents granted by USPTO on its technology, covering a total of 148 issued claims. These patent rights include 6 U.S. patents on its automation of data retrieval and sorting of data stored in multidimensional arrays technology for a total of 136 issued claims. Timeline, through its wholly owned subsidiary, WorkWise Software, Inc., holds 1 U.S. patent with 12 issued claims on a method of automating the monitoring and processing of data in data bases. It also has granted patents in Australia, Canada, China, Hong Kong, Israel, Korea, Mexico, and Singapore. The company was founded in 1977 and is headquartered in Seattle, Washington. With 4.19 million shares outstanding and 5,000 shares declared short as of January 2008, there is a failure to deliver in shares of TMLN.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 1,850,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
